| General Information | |
|---|---|
| ZINC ID | ZINC000028710498 |
| Molecular Weight (Da) | 367 |
| SMILES | CCCCCNc1ccc(C(=O)c2cccc3ccccc23)c2ccccc12 |
| Molecular Formula | C26N1O1 |
| Action | Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 118.202 |
| HBA | 1 |
| HBD | 1 |
| Rotatable Bonds | 7 |
| Heavy Atoms | 28 |
| LogP | 6.645 |
| Activity (Ki) in nM | 120.226 |
| Polar Surface Area (PSA) | 29.1 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | + |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | + |
| Cyp3a4 substrate | - |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | + |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | + |
| Cyp1a2 inhibition | + |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | + |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 1.133 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 20 |
| Fraction csp3 | 0.19 |
| Ilogp | 3.99 |
| Xlogp3 | 7.54 |
| Wlogp | 6.64 |
| Mlogp | 4.96 |
| Silicos-it log p | 6.76 |
| Consensus log p | 5.98 |
| Esol log s | -6.94 |
| Esol solubility (mg/ml) | 0.0000427 |
| Esol solubility (mol/l) | 0.00000011 |
| Esol class | Poorly sol |
| Ali log s | -7.99 |
| Ali solubility (mg/ml) | 0.00000379 |
| Ali solubility (mol/l) | 1.03E-08 |
| Ali class | Poorly sol |
| Silicos-it logsw | -10.22 |
| Silicos-it solubility (mg/ml) | 2.21E-08 |
| Silicos-it solubility (mol/l) | 6.03E-11 |
| Silicos-it class | Insoluble |
| Pgp substrate | |
| Log kp (cm/s) | -3.19 |
| Lipinski number of violations | 1 |
| Ghose number of violations | 1 |
| Veber number of violations | 0 |
| Egan number of violations | 1 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 2.24 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -7.24 |
| Logd | 4.892 |
| Logp | 6.757 |
| F (20%) | 0.977 |
| F (30%) | 1 |
| Mdck | 8.65E-06 |
| Ppb | 1 |
| Vdss | 0.972 |
| Fu | 0.003 |
| Cyp1a2-inh | 0.856 |
| Cyp1a2-sub | 0.203 |
| Cyp2c19-inh | 0.799 |
| Cyp2c19-sub | 0.063 |
| Cl | 4.501 |
| T12 | 0.017 |
| H-ht | 0.355 |
| Dili | 0.941 |
| Roa | 0.122 |
| Fdamdd | 0.245 |
| Skinsen | 0.94 |
| Ec | 0.003 |
| Ei | 0.975 |
| Respiratory | 0.12 |
| Bcf | 1.808 |
| Igc50 | 5.483 |
| Lc50 | 5.524 |
| Lc50dm | 6.377 |
| Nr-ar | 0.218 |
| Nr-ar-lbd | 0.031 |
| Nr-ahr | 0.953 |
| Nr-aromatase | 0.707 |
| Nr-er | 0.904 |
| Nr-er-lbd | 0.704 |
| Nr-ppar-gamma | 0.023 |
| Sr-are | 0.905 |
| Sr-atad5 | 0.95 |
| Sr-hse | 0.179 |
| Sr-mmp | 0.86 |
| Sr-p53 | 0.457 |
| Vol | 414.812 |
| Dense | 0.885 |
| Flex | 0.304 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 0 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 4 |
| Surechembl | 0 |
| Nonbiodegradable | 0 |
| Skin sensitization | 3 |
| Acute aquatic toxicity | 0 |
| Toxicophores | 1 |
| Qed | 0.287 |
| Synth | 1.973 |
| Fsp3 | 0.192 |
| Mce-18 | 20 |
| Natural product-likeness | -0.619 |
| Alarm nmr | 1 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | 0 |
| Gsk | Rejected |
| Goldentriangle | Accepted |